среда, 17 ноября 2010 г.

Female sexual dysfunction declared non-existent

The authoritative British scientific journal British Medical Journal published an article whose author argues that the diagnosis of female sexual dysfunction was fabricated with the participation of large pharmaceutical companies seeking to start production and sale of prescribed drugs, reports PhysOrg.


The author, journalist and lecturer at the Australian University of Newcastle, Ray Moynihan (Ray Moynihan), conducted an independent investigation into the matter and described his results in his new book Sex, Lies and Pharmaceuticals («Sex, Lies, and drugs).


Moynihan argues that employees of pharmaceutical companies created a new diagnosis with the help of paid reputable physicians. In the course of this work was carried out studies proving the prevalence of the problem. In addition, the developed diagnostic criteria, convincing women that their sexual difficulties are a medical problem and need treatment.


The efforts of pharmaceutical companies have diagnoses of sexual dysfunction, as contained in the International Classification of Diseases 10 th revision (ICD-10) under the rubric of F52 (eg, failure of genital response, lack or loss of sexual desire, etc.). The results of research conducted without financial support from drug makers often call into question the legality of raising such a diagnosis.
As an example, the author gives an educational course for U.S. doctors, organized by pharmaceutical giant Pfizer. It was alleged that sexual dysfunction is suffering 63 per cent women and can help them by appointing testosterone and sildenafil (Viagra) with behavioral therapy.


Despite the fact that drugs designed to treat sexual dysfunction in women who have not been approved for use by the Office of Food and Drug Administration (FDA), an array of scientific papers on the problem of sexual dysfunction remained, creating an impression of the necessity of finding new drugs, says Moynihan.


The output of this publication was the approval of the need to change the approval process of new diagnoses in such a way as to best protect it from the influence of pharmaceutical companies

Комментариев нет:

Отправить комментарий